Phase 1
Sarcoidosis ILD
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Tofacitinib (XELJANZ®) is an oral, small molecule drug called a Janus kinase (JAK) inhibitor. 

Study Purpose

This is a pilot study to determine whether further research is warranted to assess whether tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis. The primary endpoint for this study is a 50% or greater reduction in corticosteroid requirement.

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >